NCT05201911View on ClinicalTrials.gov

A Study to Characterize the Biodistribution of 124I-Labeled AT-03 in Patients With Systemic Amyloidosis

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

November 30, 2021

Primary Completion Date

September 6, 2022

Study Completion Date

September 6, 2022

Conditions
Amyloidosis; Systemic
Interventions
DRUG

124I-AT03

IV injection of the radiolabeled compound on day 1 followed by Positron Emission Tomography/Computed Tomography (PET/CT) scanning on Days 2, 4 and 8 to. The first 3 subjects enrolled will have two additional scans on Day 1.

Trial Locations (1)

37920

University of Tennessee Medical Center, Knoxville

Sponsors

Lead Sponsor

Attralus, Inc.
All Listed Sponsors
lead

Attralus, Inc.

INDUSTRY

NCT05201911 - A Study to Characterize the Biodistribution of 124I-Labeled AT-03 in Patients With Systemic Amyloidosis | Biotech Hunter | Biotech Hunter